GERD, Obesity
Conditions
Keywords
GERD, Bariatric surgery, Endoscopic sleeve gastroplasty, Sleeve gastrectomy, Roux-en-Y gastric bypass
Brief summary
GERD is common in the obese population. Bariatric procedures are the mainstay of therapy for these patients. Bariatric procedures can be surgical (Roux-en-Y gastric bypass and Vertical sleeve gastrectomy) or endoscopic (endoscopic sleeve gastroplasty). The rate of GERD after either treatment is unknown as is the rate of silent reflux. The study primary objective is to assess the incidence rate of GERD in bariatric patients that undergo either therapy.
Detailed description
GERD is a prevalent condition worldwide, estimated to be around 20-30 % in North America. Obesity is rapidly increasing with an estimated prevalence of 66% in the adult population in the United States. GERD symptoms are common in the obese population with data showing weekly GERD symptoms in 34.6% and erosive esophagitis 26.9% in people with BMI \> 30 Kg/m2. Presently, bariatric procedures are the only sustainable method to address morbid obesity and its resulting comorbidities. There are endoscopic and surgical bariatric procedures. The natural history of GERD symptoms in this population after undergoing a bariatric treatment is scarce or conflicting. Moreover, silent or asymptomatic GERD prevalence has not been well established preoperatively. Evaluation and documentation of GERD may potentially change the planned bariatric procedure and avoid unnecessary additional surgeries or procedures to address symptomatic post-operative GERD. The investigators hypothesized that GERD is more prevalent in patients undergoing surgical bariatric procedures, specifically laparoscopic vertical sleeve gastrectomy (VSG). This multi-center, prospective, cohort study can potentially clarify current debatable data, based mostly on retrospective studies, and can help clinicians to select the most appropriate bariatric treatment for the patients. Most importantly, by selecting the best approach based on preoperative GERD studies it could prevent long term complications of GERD and further unnecessary procedures for the bariatric patient.
Interventions
PROCEDUREEndoscopy
endoscopic suturing of stomach
PROCEDURESurgery
Vertical sleeve gastrectomy (VSG) surgical reduction of stomach, or (RYGBP) , or gastric bypass procedure
Sponsors
Johns Hopkins University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Inclusion criteria
* BMI ≥ 30 Kg/m2 * Patients scheduled to undergo a bariatric weight loss procedure (endoscopic or surgical) * Patients older than 18 years and younger than 75 years of age at time of consent * Patients able to provide written informed consent on the Institutional review board (IRB) approved informed consent form * Patients willing and able to comply with study requirements for follow-up
Exclusion criteria
* Any patient with BMI \< 30 Kg/m2 * Patients treated with intragastric balloons. * Pre-existing esophageal stenosis/stricture preventing advancement of an endoscope during screening/baseline Esophagogastroduodenoscopy (EGD) * Esophageal, gastric or duodenal malignancy * Severe medical comorbidities precluding endoscopy, or limiting life expectancy to less than 2 years in the judgment of the endoscopist * Uncontrolled coagulopathy or inability to be off anticoagulation or anti-platelet medication (ASA, Plavix) for 1 week prior to and 2 weeks after each endoscopy * Active fungal esophagitis * Known portal hypertension, visible esophageal or gastric varices, or history of esophageal varices * General poor health, multiple co-morbidities placing the patient at risk, or otherwise unsuitable for trial participation * Pregnant or planning to become pregnant during period of study participation * Patient refuses or is unable to provide written informed consent * Prior bariatric treatment procedure * Prior surgical or endoscopic anti-reflux procedure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of participants with GERD based on symptoms, and abnormal acid exposure time and/or reflux esophagitis | 1 year | GERD symptoms, esophageal acid exposure time and/or esophagitis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Difference in BMI after the bariatric procedure | 5 years | change in weight in Kg and height in m (BMI=Kg/m) before and after treatment |
| Reflux esophagitis | 5 years | Incidence of GERD-related complications |
| GERD severity based on standardized Reflux Disease Questionnaire (RDQ) | 3,6,12,24,26,48, and 60 months post procedure | GERD severity based on standardized Reflux Disease Questionnaire (RDQ) questionnaire (score 12-72; the greater the score, the greater the severity) |
| GERD severity as assessed by GERD-Health related quality of life (HRQL) score | 3,6,12,24,26,48, and 60 months post procedure | GERD-Health related quality of life (HRQL) score (score 0-53; the greater the score,the worse the quality of life) will be used for this assessment |
| Percentage of participants on daily or twice daily PPI for GERD symptoms control, regardless of pH-monitoring results | 5 years | Proportion of patients being treated with medication (PPI) |
| Percent of patients with abnormal esophageal acid exposure time > 6% defined by Bravo pH monitoring (96 hours) | 1 year | Abnormal esophageal acid exposure time (AET) |
| Percentage of excess body weight (EBW) loss and total body weight loss (TBWL) | 5 years | Change in body weight after treatment with endoscopy and surgery (compare groups) |
| Prevalence and incidence of silent reflux | 1 year | Proportion of patients with abnormal AET without symptoms after bariatric treatment procedure |
| Percentage of patients with GERD at baseline in whom the planned bariatric intervention was changed due to abnormal ph testing or presence of erosive esophagitis, Barrett's esophagus, reflux related esophageal stricture | 1 year | Proportion of patients with change in treatment plan after diagnostic evaluation |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORMarcia I Canto, MD
Johns Hopkins University
Outcome results
None listed